OxyContin maker says it will no longer market opioid to doctors

OxyContin maker says it will no longer market opioid to doctors

OxyContin maker says it will no longer market opioid to doctors

In a surprise move, Purdue Pharma, the manufacturer of the opiate painkiller OxyContin, has said that it will reduce its direct sales force and stop the direct marketing of opiates to doctors.

Most recently, Alabama Attorney General Steve Marshall filed a lawsuit on Tuesday accusing Purdue of deceptively marketing prescription opioids to generate billions of dollars in sales. The remaining 200 sales reps will focus on non-opioid drugs such as Symproic, the company said. The company will still handle requests from doctors who have questions about drugs such as OxyContin, through its medical affairs department.

He said Purdue's decision is helpful, but it won't make a major difference unless other opioid drug companies do the same.

Codeine drugs may soon only be available by prescription.

More news: Chris Hemsworth would love to do Crocodile Dundee reboot

Purdue Pharma pleaded guilty in 2007 to felony charges for false marketing of OxyContin and paid $635 million as a result.

"We have restructured and significantly reduced our commercial operation and will no longer be promoting opioids to prescribers", Purdue said in a statement.

"Effective Monday, February 12, 2018, our field sales organization will no longer be visiting your offices to engage you in discussions about our opioid products", Kwarcinski said in the letter, which was released to media outlets.

Alabama last Tuesday became the latest state to file a lawsuit accusing the private CT company of fueling the USA epidemic by misrepresenting the risks and benefits of opioids. Opioid litigation increased sharply in 2017 when hundreds of cities, counties and states sued opioid makers, wholesalers, distributors and marketers. Opioids also have been blamed for a resurgence in heroin use. Instead, the company said it will direct prescribers to materials published by the Centers for Disease Control and Prevention and the office of the US surgeon general. "We are committed to being part of the solution by partnering with local law enforcement, state and local government agencies, and community groups across the country". It later acknowledged that its promotions exaggerated the safety of the drug and minimized its risk for addiction.

Related news